Needham & Company Reiterates Buy Rating, $8 Price Target on Trevi Therapeutics (TRVI) Ahead of Upcoming Trial Data, "Focus Now Turns to The Ph 2b/3 PRISM Trial"
Tweet Send to a Friend
Needham & Company analyst Serge Belanger reiterated a Buy rating and $8.00 price target on Trevi Therapeutics (NASDAQ: TRVI), ahead ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
